These findings suggest that the Irish population has a markedly lower incidence of BRAF and NRAS mutations in melanomas than that previously reported in other population cohorts and will therefore potentially benefit less from the success of BRAF and MEK inhibitor therapy as well as any future NRAS-targeted treatments. This evidence concerns the gene NRAS and melanoma.